Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study

BACKGROUND: The epidermal growth factor receptor (EGFR) is over-expressed in 70–75% of colorectal adenocarcinomas (CRC). The anti-EGFR monoclonal antibody cetuximab has been approved for the treatment of metastatic CRC, however tumor response to cetuximab has not been found to be associated with EGF...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Razis, Evangelia, Briasoulis, Evangelos, Vrettou, Eleni, Skarlos, Dimosthenis V, Papamichael, Dimitrios, Kostopoulos, Ioannis, Samantas, Epaminontas, Xanthakis, Ioannis, Bobos, Mattheos, Galanidi, Eleni, Bai, Maria, Gikonti, Ioanna, Koukouma, Alona, Kafiri, Georgia, Papakostas, Pavlos, Kalogeras, Konstantine T, Kosmidis, Paris, Fountzilas, George
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2008
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2527615/
https://ncbi.nlm.nih.gov/pubmed/18700047
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-8-234
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller